To evaluate the efficacy and safety of menin inhibitors in adult patients with NPM1-mutated or KMT2A-rearranged relapsed/refractory acute myeloid leukemia.
Conducted a systematic review and meta-analysis
Searched multiple databases including Web of Science
Included prospective cohort studies and randomized controlled trials
Assessed overall response rate and adverse events among patients treated with menin inhibitors
Pooled overall response rate was 59.7% among included studies
Higher complete response rate observed in NPM1-mutated patients compared to KMT2A-rearranged patients
Combination therapy with venetoclax and azacitidine significantly improved both overall and complete response rates